SPOTLIGHT -
Waltham, MA-Interleukin Genetics Inc. has received a U.S. patent for a method that uses specific genetic markers to identify people with diabetes who are at an increased risk of retinopathy.
Eyenuk gets greenlight to market AI screening system in European Union
Commercial real estate and your practice, part two with Colin Carr
Study: Retina specialists gain awareness of biosimilars
Tips, tricks, what to dos and what not to dos on how you can save money as a healthcare provider on your commercial real estate (Part 1)
HuidaGene Therapeutics gains FDA clearance for multinational clinical trial of investigational new drug
Foundation Fighting Blindness to kick off PRPH2 and Associated Retinal Diseases Workshop